Siplizumab

DRUG7 trials

Conditions

Anemia, Sickle CellAutoimmune HepatitisAutoimmune Liver DiseaseChimeraCirrhosis, LiverEnd Stage Liver DIseaseGamma Delta Hepatosplenic T-Cell LymphomaHidradenitis Suppurativa

Early Phase 1

An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

RecruitingNCT06326476

University of Alabama at BirminghamHidradenitis Suppurativa

Start: 2025-05-09End: 2027-07-31Target: 12Updated: 2025-05-29

Phase 1

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

CompletedNCT01445535

National Cancer Institute (NCI)Gamma Delta Hepatosplenic T-Cell Lymphoma, NK T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma +1

Start: 2009-01-13End: 2020-10-22Updated: 2021-11-03

Siplizumab in T1DM

TerminatedNCT05574335

National Institute of Allergy and Infectious Diseases (NIAID)Type 1 Diabetes Mellitus

Start: 2023-04-26End: 2025-10-20Updated: 2026-02-11

Delayed Tolerance Through Mixed Chimerism

Active, not recruitingNCT05900401

Massachusetts General HospitalChimera, Kidney Failure, Kidney Transplant; Complications

Start: 2023-10-01End: 2030-12-31Target: 20Updated: 2025-12-09

Siplizumab for Sickle Cell Disease Transplant

TerminatedNCT06078696

Columbia UniversityAnemia, Sickle Cell

Start: 2023-09-28End: 2025-12-11Updated: 2026-02-27

A Study of SIPLIZUMAB in AILD and LT Patients

RecruitingNCT06455280

Elizabeth C. VernaAutoimmune Hepatitis, Autoimmune Liver Disease, Cirrhosis, Liver +3

Start: 2024-09-11End: 2028-03-31Target: 8Updated: 2025-11-24

Phase 2

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Not yet recruitingNCT07508787

Nefro Avillion Clinical Development, LLCRenal Transplant Failure and Rejection

Start: 2026-04-29End: 2028-03-28Target: 120Updated: 2026-04-02

Siplizumab

Sponsors

Conditions

Early Phase 1

Phase 1

Phase 2